Wound Management News

The FDA and Teva Pharmaceuticals announced that Teva has voluntarily suspended sales, marketing and distribution of the Zecuity patch.

Most surveyed dermatology patients preferred professional attire, including a white coat, for their dermatologists across treatment settings, according to study results recently published in JAMA Dermatology.

The FDA announced its investigation of the risk for serious burns and potential permanent scarring with the use of the Zecuity patch for treating migraines.

BALTIMORE — The investigational herpes simplex virus-2 vaccine GEN-003 was well-tolerated and reduced viral shedding and genital lesions up to 1 year after vaccination, according to data presented at the Annual Conference on Vaccine Research.

Surveyed participants reported that they had a significantly better perception of the appearance of linear scars compared with zigzag scars in three separate facial locations, according to study results published in JAMA Facial Plastic Surgery.

Focus Diagnostics has recalled its laboratory examination kits for herpes simplex virus 1 and 2 and group A streptococcus infection due to inaccurate test results, according to a press release. The FDA identified the event as a class 1 recall, as use of the devices may result in serious injuries or death.

Pooled data from phase 2 and phase 3 studies suggest the efficacy and safety of Paratek Pharmaceutical’s investigational broad-spectrum antibiotic omadacycline is comparable to Zyvox in the treatment of complicated skin and skin structure infections in adults.

A study that used electronic bottle caps to record each time a pill bottle was opened showed that patients commonly overstated their adherence to antibiotic regimens for skin and soft tissue infections.

Patients who received a series of light-emitting diode low-level light therapy sessions after thyroidectomy showed improved scar quality compared with a control group, according to recent research.

Impavido, the only FDA-approved oral treatment for visceral, mucosal and cutaneous leishmaniasis, is now available in the United States, according to press release.